Lunit will present 5 abstracts at ESMO 2022


Lunit said it plans to present five abstracts highlighting the effectiveness of Lunit SCOPE, its artificial intelligence (AI)-biomarker platform, at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. September 9-13.

Lunit plans to present five new studies at this year’s European Society for Medical Oncology Congress.

The upcoming event is expected to attract over 25,000 oncology professionals from over 160 countries.

During the conference, Lunit will present studies related to the use of Lunit SCOPE to predict breast cancer treatment effect, measure tumor purity, verify PD-L1 AI performance of urothelial cancer , provide quantitative analysis of neuroendocrine tumor infiltrating lymphocytes (TILs), and discover novel antibody-drug conjugate targets.

Particularly, regarding the study related to the prediction of breast cancer treatment effects, a research team led by Professors Song Sang-yong, Cho Eun-yoon and Cho Soo-youn from Samsung Medical Center confirmed that Lunit SCOPE could read human epidermal growth factor receptor 2. (HER2) expression level in patients with HER2 positive early breast cancer at the level of a human pathologist.

“We analyzed expression levels of HER2, an important breast cancer biomarker, using Lunit SCOPE in patients undergoing breast cancer treatment, and confirmed high agreement with results read by pathologists using traditional methods,” Professor Song said. “Through additional assessments of lymphocytes at the cellular and tumor-infiltrating level, we have confirmed that the Lunit Scope can play an ancillary role in predicting the therapeutic effect of prior chemotherapy.”

Other studies include assessment of tumor purity directly from H&E whole slide images using Lunit SCOPE AI (AI-P) technology and concordance between AI-P and allele frequency variants (VAF) as determined by next-generation sequencing (NGS), and demonstration of accuracy of Lunit SCOPE PD-L1 combined positive score (CPS) levels in 543 cases of urothelial carcinoma.

The company will also unveil the platform’s ability to use the AI-powered TIL and PD-L1 CPS analysis solution as a predictive biomarker of immune checkpoint inhibitor (ICI) response in neuroendocrine neoplasms (NENs). .

Lunit will publish another study on Lunit SCOPE in the discovery of new targets for antibody-drug conjugates (ADCs) by precisely analyzing linked NGS and immunohistochemical data in tumors, highlighting the potential of multimodal analysis linking molecular and visual.

“We expect the value of the Lunit SCOPE to increase at the ESMO annual meeting as we present the results of using the platform in various types of cancer,” said Lunit CEO Suh Beom-seok. .


About Author

Comments are closed.